Table 5.
Comparison of staged-2 clinical characteristics of SRH between the ALPPS group and PVL group.
| Variables |
ALPPS
(N = 6) |
PVL group (N = 5) | P-value |
|---|---|---|---|
| TACE after stage 1 | 0 | 2 | NA |
| Time to second stage, days | 14.6(12–22) | 44.2(21–83) | 0.016 |
| Increased in volume per day, ml | 12.7 (5.2–14.9) |
9.8(1.2–18.6) | 0.522 |
| Ratio of gained standard volume per day, % | 1.2(0.5–1.5) | 1.0(0.1–1.8) | 0.536 |
| Operative time of stage 2, minutes | 338.6(140–515) | 255.2(185–450) | 0.274 |
| Blood loss, ml | 1016.7 (300–2,500) |
940.0 (350–1,500) |
0.855 |
| PHLF, n(%) | 1(16.7%) | 2(40%) | 0.545 |
| Clavien-Dindo grade | |||
| Grade 1/2 | 3/3 | 3/2 | 1.000 |
| Bile leak, n(%) | 3(50%) | 3(60%) | 1.000 |
| Hospital stay after surgery, days | 11(8-19) | 20(8–47) | 0.230 |
| Recurrence within 1 year, n (%) | 3(50%) | 1(20%) | 0.545 |